Replimune Group, Inc. (REPL)
14.69
-0.08
(-0.54%)
USD |
NASDAQ |
Aug 24, 16:00
14.69
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Total Assets (Quarterly) : 252.45M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 252.45M |
| March 31, 2026 | 332.39M |
| December 31, 2025 | 333.59M |
| September 30, 2025 | 389.45M |
| June 30, 2025 | 469.51M |
| March 31, 2025 | 551.33M |
| December 31, 2024 | 603.63M |
| September 30, 2024 | 498.20M |
| June 30, 2024 | 534.96M |
| March 31, 2024 | 487.72M |
| December 31, 2023 | 532.93M |
| September 30, 2023 | 562.40M |
| June 30, 2023 | 603.89M |
| March 31, 2023 | 646.59M |
| December 31, 2022 | 678.55M |
| September 30, 2022 | 436.10M |
| June 30, 2022 | 459.43M |
| March 31, 2022 | 461.19M |
| December 31, 2021 | 485.28M |
| Date | Value |
|---|---|
| September 30, 2021 | 503.46M |
| June 30, 2021 | 523.72M |
| March 31, 2021 | 543.10M |
| December 31, 2020 | 559.20M |
| September 30, 2020 | 314.24M |
| June 30, 2020 | 329.58M |
| March 31, 2020 | 234.10M |
| December 31, 2019 | 250.42M |
| September 30, 2019 | 151.44M |
| June 30, 2019 | 143.54M |
| March 31, 2019 | 154.33M |
| December 31, 2018 | 152.19M |
| September 30, 2018 | 153.82M |
| June 30, 2018 | 59.29M |
| March 31, 2018 | 65.15M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 22.82M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Moderna, Inc. | 10.96B |
| Kalaris Therapeutics, Inc. | 99.54M |
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 146.80M |
| Shareholders Equity (Quarterly) | 105.64M |
| Debt to Equity Ratio | 1.060 |
| Current Ratio | 5.228 |
| Net Debt Paydown Yield | -0.77% |